Table 1.

Comparison of clinicopathologic characteristics between the KRASwt, KRASG12C, and KRASother groups.

CharacteristicTotal cohort (n = 604)KRASwt (n = 374)KRASG12C (n = 95)KRASother (n = 135)
Age at resection, years68 (62–74)68 (62–74)69 (64–75)67 (61–73)
Sex
 Male202 (33)130 (35)34 (36)38 (28)
 Female402 (67)244 (65)61 (64)97 (72)
Smoking status
 Never138 (23)125 (33)4 (4.2)9 (6.7)
 Ever466 (77)249 (67)91 (96)126 (93)
Pack-years (n = 465)27 (15–45)10 (0–30)27 (16–43)30 (14–46)
FEV1 (n = 592)94 (83–106)95 (84–108)90 (77–104)94 (83–105)
DLCO (n = 586)84 (69–97)87 (72–99)79 (64–92)80 (66–95)
SUVmax (n = 537)3.7 (1.9–7.2)3.4 (1.8–6.7)4.1 (2.3–8.1)4.0 (2.1–7.5)
Operative approach
 VATS521 (86)324 (87)79 (83)118 (87)
 Open83 (14)50 (13)16 (17)17 (13)
Operative procedure
 Lobectomy or pneumonectomy390 (65)245 (66)61 (64)84 (62)
 Sublobar214 (35)129 (34)34 (36)51 (38)
Pathologic tumor size, cm1.8 (1.2–2.8)1.8 (1.2–2.8)1.8 (1.3–2.7)2.0 (1.4–3.1)
LVI (n = 599)248 (41)150 (41)49 (52)49 (36)
VPI109 (18)70 (19)20 (21)19 (14)
STAS (n = 544)337 (62)183 (55)68 (75)86 (70)
Histologic subtype
 Lepidic88 (15)59 (16)10 (11)19 (14)
 Acinar368 (61)218 (58)64 (67)86 (64)
 Papillary43 (7.1)28 (7.5)4 (4.2)11 (8.1)
 Micropapillary37 (6.1)25 (6.7)5 (5.3)7 (5.2)
 Solid68 (11)44 (12)12 (13)12 (8.9)
pN status (n = 603)
 N0506 (84)311 (83)75 (79)120 (89)
 N1 or N297 (16)62 (17)20 (21)15 (11)
pStage
 I447 (74)278 (74)66 (69)103 (76)
 II95 (16)61 (16)16 (17)18 (13)
 III62 (10)35 (9.4)13 (14)14 (10)
PD-L1 status
 None (<1%)343 (57)233 (62)45 (47)65 (48)
 Low (1–49%)85 (14)47 (13)15 (16)23 (17)
 High (≥50%)176 (29)94 (25)35 (37)47 (35)
Adjuvant therapy116 (19)68 (18)21 (22)27 (20)
  • Note: Data are n (%) or median (IQR).

  • Abbreviations: FEV1, forced expiratory volume in 1 second; LVI, lymphovascular invasion; SUVmax, maximum standardized uptake value.